Molecular neuropathology of Alzheimer's disease: in situ hybridization studies
- PMID: 2110505
- PMCID: PMC11567306
- DOI: 10.1007/BF00733642
Molecular neuropathology of Alzheimer's disease: in situ hybridization studies
Abstract
1. Abundant senile plaques and neurofibrillary tangles in certain brain regions constitute the major neuropathological characteristics of Alzheimer's disease. Recent work has established that the amyloid beta protein, which is derived from a large precursor, constitutes the major constituent of plaque amyloid, whereas the microtubule-associated protein tau is a component of the paired helical filament, the major constituent of neurofibrillary tangles. 2. Multiple isoforms of amyloid beta protein precursor and tau protein are produced from a single gene through alternative RNA splicing. By Northern blotting amyloid beta protein precursor transcripts are found throughout central and peripheral tissues, whereas tau protein transcripts are only found in the nervous system. 3. In the central nervous system the cellular localization of amyloid beta protein precursor and tau protein transcripts is neuronal. The cells affected in Alzheimer's disease patients produce both types of transcripts; however, the various transcripts are also found in cells not affected in the course of the disease. At present, there exists no evidence to suggest that an overproduction of amyloid beta protein precursor or tau protein is the reason for plaque and tangle formation. The formation of the latter probably results from posttranslational events.
Similar articles
-
Expression of the Alzheimer amyloid precursor gene transcripts in the human brain.Neuron. 1988 Oct;1(8):669-77. doi: 10.1016/0896-6273(88)90166-3. Neuron. 1988. PMID: 2908447
-
Relation of neuronal APP-751/APP-695 mRNA ratio and neuritic plaque density in Alzheimer's disease.Science. 1990 May 18;248(4957):854-7. doi: 10.1126/science.2111579. Science. 1990. PMID: 2111579
-
Expression and cellular localization of amyloid beta-protein precursor transcripts in normal human brain and in Alzheimer's disease.Brain Res Mol Brain Res. 1989 Nov;6(2-3):143-50. doi: 10.1016/0169-328x(89)90048-x. Brain Res Mol Brain Res. 1989. PMID: 2515408
-
The amyloid peptide and its precursor in Alzheimer's disease.Rev Neurosci. 1995 Oct-Dec;6(4):287-316. Rev Neurosci. 1995. PMID: 8845971 Review.
-
Molecular genetics of Alzheimer's disease and the amyloid beta peptide precursor gene.Ann Med. 1989;21(2):91-4. doi: 10.3109/07853898909149191. Ann Med. 1989. PMID: 2504259 Review.
Cited by
-
Neuroprotective Effects of the Psychoactive Compound Biatractylolide (BD) in Alzheimer's Disease.Molecules. 2022 Nov 28;27(23):8294. doi: 10.3390/molecules27238294. Molecules. 2022. PMID: 36500385 Free PMC article.
-
Diverse, evolving conformer populations drive distinct phenotypes in frontotemporal lobar degeneration caused by the same MAPT-P301L mutation.Acta Neuropathol. 2020 Jun;139(6):1045-1070. doi: 10.1007/s00401-020-02148-4. Epub 2020 Mar 26. Acta Neuropathol. 2020. PMID: 32219515 Free PMC article.
-
Mitochondrial permeability transition pore in Alzheimer's disease: cyclophilin D and amyloid beta.Biochim Biophys Acta. 2010 Jan;1802(1):198-204. doi: 10.1016/j.bbadis.2009.07.005. Epub 2009 Jul 16. Biochim Biophys Acta. 2010. PMID: 19616093 Free PMC article. Review.
References
-
- Alzheimer, A. (1907). Über eine eigenartige Erkrankung der Hirnrinde.Allg. Zbl. Psychol.64146–148.
-
- Bahmanyar, S., Higgins, G. A., Goldgaber, D., Lewis, D. A., Morrison, J. H., Wilson, M. C., Shankar, S. K., and Gajdusek, D. C. (1987). Localization of amyloid beta protein mRNA in brains from patients with Alzheimer's disease.Science23777–80. - PubMed
-
- Brion, J. P., Passareiro, J. P., Nunez, J., and Flament-Durand, J. (1985). Mise en évidence immunologique de la protéine tau au niveau des lésions de dégénérescence neurofibrillaire de la maladie d'Alzheimer.Arch. Biol. (Brux.)95229–235.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical